2186: Luye Pharma Group Ltd. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Luye Pharma Group Ltd.

HKG:2186

SummaryFactSheetFinancial
Price
HK$2.24
Loss Chance
46.5%
4.71JITTA SCORE
19.60%Under Jitta Line
Jitta Ranking
Pharmaceuticals
11 / 48
Health Care
45 / 232
Hong Kong
?
300 / 2,512
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
HKG:1276
7.55
HK$62.40
140.68%
Consun Pharmaceutical Group Limited
HKG:1681
7.84
HK$14.47
19.70%
Simcere Pharmaceutical Group Limited
HKG:2096
6.59
HK$10.60
14.54%
JBM (Healthcare) Limited
HKG:2161
7.32
HK$2.41
65.99%
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
HKG:2196
6.37
HK$17.48
52.38%
Jitta Factors
Growth Opportunity (42)
Recent Business Performance (68)
Financial Strength (82)
Return to Shareholders (6)
Competitive Advantage (47)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Operating MarginExpansion
Revenue and EarningRevenue decline from 2022-2025
CapExVery High
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
4.71
19.60%
4.42
201.32%
3.81
226.27%
Pharmaceuticals
7.55
140.68%
7.84
19.70%
6.59
14.54%
COMPANY DESCRIPTION
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by trauma or surgery, and for treatment of venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes mellitus; Seroquel, Seroquel XR, Erzofri; and Rivastigmine Multi-Day Transdermal, Rotigotine transdermal, Fentanyl, and Buprenorphine patches. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Boyoubei, a denosumab injection for the treatment of postmenopausal women with osteoporosis; and Boyouping, a dulaglutide injection for glycemic control in adults. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; develops, manufactures, and commercialises of biologics; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People’s Republic of China.
www.luye.cn
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.